Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
Completed · Phase 4 · NCT02541955
Conditions: Rheumatoid Arthritis (RA)
At a glance
- Research payments reported, 2025
- $60,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 40
About the trial
- Sponsor
- Veena Ranganath, MD, MS (with Mallinckrodt)
- Tested
- Acthar (drug)
- Dates
- Started 2017-07-20; completion 2025-05-20
- Results posted
- Yes
This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
From ClinicalTrials.gov, last updated 2026-08-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Mallinckrodt Hospital Products Inc. reported $60,000 in research payments for this study in 2025 (1 payments).
Products named: Acthar
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.